New York, Jan 30, 2026, 20:47 EST — Market closed
- Johnson & Johnson shares finished nearly flat on Friday at $227.25.
- A U.S. judge dismissed a fraud lawsuit tied to the company’s talc-bankruptcy play; plaintiffs’ counsel stated an appeal is under review.
- The company also stated European Medicines Agency advisers backed an expanded utilize of its Akeega prostate-cancer drug.
Johnson & Johnson shares finished little alterd on Friday after Michael Shipp dismissed a lawsuit accapplying the company of fraud over its failed talc-bankruptcy strategy. The stock closed at $227.25, down 0.01%, after swinging between $225.34 and $228.40. Erik Haas called the claims “wholly meritless,” while plaintiffs’ lawyer Patricia Kipnis stated she was reviewing the decision with clients to discuss an appeal. (Reuters)
For investors, the talc docket remains a headline risk that can widen or narrow the stock’s “legal discount” quickly, even when day-to-day trading is calm. The fraud case is separate from the underlying cancer claims, but it sits in the same fight over how — and where — those claims obtain resolved.
The company also flagged a regulatory step in Europe that traders tfinish to treat as incremental, but worth tracking when the stock is priced for steadiness. It stated Committee for Medicinal Products for Human Use (CHMP) recommfinished expanding utilize of Akeega, a niraparib-and-abiraterone tablet, in a subset of metastatic prostate-cancer patients with BRCA1/2 mutations. “Pfinishing approval,” Henar Hevia stated, the drug could shift a tarobtained approach “earlier in the metastatic pathway.” (Jnj)
The broader market leaned lower into the weekfinish. The S&P 500 slipped 0.43% and the Dow fell 0.36%, while large-cap pharma names were mixed — Pfizer rose 1.3% and Eli Lilly and Company gained 1.27% as Johnson & Johnson edged down. The Health Care Select Sector SPDR ETF added about 0.6%. (MarketWatch)
CHMP is the scientific committee that advises the EMA; its opinions often feed into the final European Commission decision. The company stated the recommfinishation was based on its Phase 3 AMPLITUDE study and displayed a delay in disease progression — essentially, more time before scans display the cancer is obtainting worse — with an early signal on overall survival that is still maturing.
On the legal front, the tossed fraud case tarobtained the company’s “Texas two-step” approach — shifting liabilities into a new unit and then seeking bankruptcy protection — a tactic courts have rejected in the talc fight. Johnson & Johnson has stated its talc products are safe and do not contain asbestos, and it has stopped selling talc-based baby powder.
One risk for bulls: this week’s dismissal does not cap or erase the underlying talc exposure, and any appeal could extfinish the drip of court headlines. On the drug side, a positive panel opinion is not the same as a final label, and regulators can still narrow wording or inquire for more detail around safety and utilize.
U.S. markets reopen on Monday, Feb. 2, with investors watching for the next court filing in the talc dispute and any follow-through on the European review. The stock’s next calfinishar marker is its Feb. 24 ex-dividfinish date for a $1.30 quarterly payout due March 10, the company has stated. (Jnj)
Leave a Reply